An update on activated protein C (xigris) in the management of sepsis
- PMID: 20975809
- PMCID: PMC2957744
An update on activated protein C (xigris) in the management of sepsis
Figures
References
-
- Matthay MA. Severe sepsis: A new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 2001:759–762. - PubMed
-
- Bernard G, Vincent JL, Laterre PF, et al. Efficacy and safety of activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. - PubMed
-
- FDA, Center for Drug Evaluation Research 2001 Meeting Documents, March 27, 2007. Available at: www.fda.gov/ohrms/dockets/ac/cder01.htm#Anti-Infective. Accessed June 7, 2010.
-
- FDA Clinical Review, BLA#125029/0. Drotrecogin alfa (activated) [Recombinant Human Activated Protein C (rhAPC)], Xigris. Available at: www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelo.... Indianapolis: Eli Lilly; November 21, 2001. Accessed June 7, 2010.
-
- Abraham E, Laterre P-F, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332–1341. - PubMed
LinkOut - more resources
Full Text Sources